PAI
ORKA

Palo Alto Investors’s Oruka Therapeutics ORKA Stock Holding History

Palo Alto Investors’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.94M Hold
59,985
– – 0.45% 31
2025
Q4 		$1.82M Hold
59,985
– – 0.25% 38
2025
Q3 		$791K Buy
+59,985
New +$889K 0.15% 39

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Palo Alto Investors's ORKA Position: Q1 2026 in Review

Palo Alto Investors held its Oruka Therapeutics (ORKA) position steady in Q1 2026 at 59,985 shares worth $2.94M. The position accounts for 0.45% of the portfolio, ranked #31.

Palo Alto Investors first reported a position in ORKA in Q3 2025 and has held it in 3 quarters since. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • Palo Alto Investors held 59,985 shares of Oruka Therapeutics worth $2.94M as of Q1 2026.
  • Palo Alto Investors left its Oruka Therapeutics share count unchanged in Q1 2026.
  • Oruka Therapeutics made up 0.45% of Palo Alto Investors's portfolio in Q1 2026, its #31 holding.
  • Palo Alto Investors first reported a position in Oruka Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on Palo Alto Investors's 13F filing for Q1 2026, filed 15 May 2026.